Garry Banks, MD
Internal Medicine · Niceville, FLNPI 1588631493
Payments from drug & device makers
Across 793 payments — averaging $287.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$220K
- Amgen$2K
- AstraZeneca$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$646
- TELA Bio, Inc.$466
- Novo Nordisk$392
- plus $3K from 32 others
What the payments were for
- Consulting fees$7,1253%
- Speaking & faculty fees$173,70076%
- Travel & lodging$30,05413%
- Food & beverage$16,5587%
- Education$3540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 634 | $219,671 |
| Amgen | 49 | $1,722 |
| AstraZeneca | 19 | $1,577 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $646 |
| TELA Bio, Inc. | 8 | $466 |
| Novo Nordisk | 11 | $392 |
| Axsome Therapeutics, Inc. | 4 | $382 |
| Johnson & Johnson | 3 | $373 |
| AbbVie | 6 | $294 |
| Boston Scientific | 3 | $279 |
| Biohaven Pharmaceuticals, Inc. | 4 | $164 |
| Idorsia Pharmaceuticals US Inc | 3 | $160 |
| GSK | 8 | $154 |
| Medtronic | 2 | $151 |
| Esperion Therapeutics, Inc. | 2 | $148 |
| Cvrx, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Inspire Medical Systems, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $121 |
| United Therapeutics Corporation | 1 | $108 |
| Teva Pharmaceuticals USA, Inc. | 3 | $91 |
| Boehringer Ingelheim | 1 | $80 |
| Jazz Pharmaceuticals Inc. | 1 | $78 |
| Pfizer | 4 | $70 |
| Grifols USA, LLC | 3 | $42 |
| Abbott | 2 | $36 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Valinor Pharma, LLC | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Emmaus Medical, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$126,512
- MOUNJARO$66,467
- CAPLYTA$629
- FARXIGA$625
- BREZTRI$488
- Prolia$425
- OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex)$262
- VRAYLAR$250
- TEZSPIRE$246
- Auvelity$246
- EVENITY$241
- Repatha$230
- WATCHMAN FLX$144
- MAZOR X SYSTEM$127
- Barostim Neo System$125
- SPRAVATO$125
- NEXLIZET$125
- NEXLETOL$125
- NURTEC ODT$125
- Otezla$125
How this compares
$227,791 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 74 | $113,209 |
| EliquisApixaban | 96 | $99,471 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $66,091 |
| MounjaroTirzepatide | 51 | $49,856 |
| CreonLipase/Protease/Amylase | 13 | $38,736 |
| XareltoRivaroxaban | 26 | $33,355 |
| OzempicSemaglutide | 13 | $30,085 |
| JardianceEmpagliflozin | 36 | $29,528 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $26,833 |
| FarxigaDapagliflozin Propanediol | 19 | $25,861 |
| Bydureon BciseExenatide Microspheres | 11 | $19,920 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $17,201 |
| LinzessLinaclotide | 19 | $16,645 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $13,699 |
| JanuviaSitagliptin Phosphate | 11 | $11,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $219,671 | $163,065125 claims |
| PfizerEliquis | $70 | $99,47196 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $154 | $92,92497 claims |
| AbbVieCreon, Linzess, Synthroid | $294 | $57,43956 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,577 | $43,06333 claims |
| Johnson & JohnsonXarelto | $373 | $33,35526 claims |
| Novo NordiskOzempic | $392 | $30,08513 claims |
| Boehringer IngelheimJardiance | $80 | $29,52836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Niceville
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.